MGP
BMRN icon

M&G plc’s BioMarin Pharmaceuticals BMRN Stock Holding History

M&G plc’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Sell
216,096
-10,445
-5% -$572K 0.06% 199
2026
Q1 		$12.7M Buy
226,541
+2,398
+1% +$140K 0.07% 180
2025
Q4 		$13.2M Buy
224,143
+19,303
+9% +$1.05M 0.07% 185
2025
Q3 		$11.1M Buy
204,840
+6,585
+3% +$377K 0.06% 198
2025
Q2 		$10.9M Buy
+198,255
New +$11.7M 0.06% 193

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

M&G plc's BMRN Position: Q2 2026 in Review

M&G plc reduced its BioMarin Pharmaceuticals (BMRN) stake by 4.6% in Q2 2026, selling an estimated $572K and leaving 216,096 shares worth $12.3M. The position accounts for 0.06% of the portfolio, ranked #199.

M&G plc first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.2M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • M&G plc held 216,096 shares of BioMarin Pharmaceuticals worth $12.3M as of Q2 2026.
  • M&G plc sold 10,445 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $572K.
  • BioMarin Pharmaceuticals made up 0.06% of M&G plc's portfolio in Q2 2026, its #199 holding.
  • M&G plc first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • M&G plc's BioMarin Pharmaceuticals position peaked at $13.2M in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.